Selexis CHO Cells in Suspension-1

Protein Expression Capabilities

Leveraging advanced gene technology and a proprietary cell line to discover, develop and manufacture biologic drugs and vaccines, Selexis improves manufacturing safety and significantly shortens monoclonal antibody development timelines—all while lowering costs and improving protein expression levels.

Selexis has developed proprietary protein expression tools that can be used with predictability and a high commitment to safety.

For over 20 years, Selexis has built collaborations, partnerships, and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Our innovative and proprietary cell line development technologies significantly reduce the time, effort, and costs that are associated with developing high-performance mammalian cell lines used for innovative therapies. (e.g., mAbs, growth factors and enzymes).

The increaing complexity of these novel therapeutic proteins place immense pressure on the Chinese Hamster Ovary (CHO) cell lines which is the standard workhorse typically used to express such molecules. This led Selexis to utilize it's multi-disciplinary expertise to engineer and create the CHO-Mplus libraries that address expression bottlenecks related to transcription, translation, DNA repair, secretion, protein folding, glycosylation etc. Utilizing modular workflows the optimal CHO host for expression and production of the desired protein candidate can be identified. Leveraging a robust panel of analytical methods early in the cell line development process allows for early characterization of the expressed protein to ensure that only cell clones producing proteins with the desired attributes are advanced through the development process. To mitigate manufacturing risks, Selexis has also developed cell line characterization modules based on next generation sequencing (NGS) methods. These allow for comprehensive genetic characterization, clonality assessment and authentication of the CHO manufacturing cell lines.

At Selexis, we believe in the promise of these newer biologics. We have committed significant resources to ensure our technologies can meet the challenges that these non-natural proteins present.

 

AT A GLANCE

  • Founded in 2001
  • GLOBALLY TRUSTED: Partners in more than 42 countries, representing the complete spectrum of life sciences—from research laboratories and biotech startups to big pharma
  • VALIDATED: There are more than 140 Selexis-generated research cell banks being used for clinical programs and eight marketed products in cancer, autoimmune/inflammatory and metabolic/genetic disorders
  • FOCUS ON INNOVATION: 210 granted patents that cover innovations in genetic elements, procedures/ transfection, cell line engineering, and devices related to cell line development and protein expression
  • RAPID: Can move from transfection to banking of a high-expressing and stable production-ready research cell bank in as little as 8-12 weeks depending on cloaning strategy.
1903-selexis-corpo-200
 

SUREtechnology PLATFORM

  • Advanced gene transfection technology and procedures

  • Proprietary CHO-K1 cell line

  • Defined media and feed strategies

  • Product and cell line analytics/characterization
Selexis-Website-Test-Image-7